The in vivo experiments also support a role for the LIMA1-MYO5B axis in this process: mice receiving LRP5-overexpressing CM from LIMA1-knockdown osteocytes exhibited greater tumor infiltration than those treated with normal LRP5-overexpressing CM, whereas the tumor-suppressive effect of LRP5-overexpressing CM was significantly attenuated in mice bearing MYO5B-knockdown EO771 tumors. This evidence concerns the gene MYO5B and neoplasm.